Pharming Group N.V. (ENXTAM:PHARM) will look for acquisitions. Sijmen de Vries, Chief Executive Officer said, "we will look to invest in acquisitions and in-licensing of new development opportunities that are near term to the market so we can launch additional products very rapidly beyond leniolisib. And we provide no further specific guidance for 2021”.